

Bimzelx® (bimekizumab-bkzx) – New device approvals

- On October 14, 2024, <u>UCB announced</u> the FDA approval of a 2 mL pre-filled syringe and pre-filled autoinjector, each containing 320 mg of Bimzelx[®] (bimekizumab-bkzx).
 - These new device presentations add to the currently available 1 mL administration options, each containing 160 mg of Bimzelx.
- The new 320 mg devices mean that patients requiring a 320 mg dose of Bimzelx will have options for single-injection administration.
- Bimzelx is approved for the treatment of plaque psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis.
- For plaque psoriasis, the recommended dosage of Bimzelx is 320 mg by subcutaneous (SC) injection at weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter. For patients weighing 120 kg or more, a dosage of 320 mg every 4 weeks after week 16 can be considered.
- For psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis, the recommended dosage of Bimzelx is 160 mg by SC injection every 4 weeks.
- UCB plans to launch the 320 mg device presentations in the first quarter of 2025.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.